Denali & Biogen Halt Parkinson's Drug BIIB122 After Phase 2b Failure
summarizeSummary
Denali Therapeutics and Biogen are discontinuing their Parkinson's disease drug BIIB122 after it failed to meet primary and secondary endpoints in the Phase 2b LUMA study. This is a significant clinical setback, removing a key pipeline asset for a major indication. The news follows a recent period of mixed developments for Denali, including an FDA approval for AVLAYAH but also a collaboration termination with Takeda. Denali will continue a separate Phase 2a study for BIIB122 in LRRK2 variant carriers, with data anticipated in the first half of 2027.
At the time of this announcement, DNLI was trading at $17.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $12.58 to $23.77. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.